Cellectis S.A.

ENXTPA:ALCLS Stock Report

Market Cap: €108.4m

Cellectis Management

Management criteria checks 2/4

Cellectis' CEO is Andre Choulika, appointed in Jan 1999, has a tenure of 26.33 years. total yearly compensation is $937.54K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.46% of the company’s shares, worth €1.59M. The average tenure of the management team and the board of directors is 4.8 years and 8.2 years respectively.

Key information

Andre Choulika

Chief executive officer

US$937.5k

Total compensation

CEO salary percentage100.0%
CEO tenure26.3yrs
CEO ownership1.5%
Management average tenure4.8yrs
Board average tenure8.2yrs

Recent management updates

Recent updates

Improved Revenues Required Before Cellectis S.A. (EPA:ALCLS) Stock's 32% Jump Looks Justified

May 04
Improved Revenues Required Before Cellectis S.A. (EPA:ALCLS) Stock's 32% Jump Looks Justified

Is Cellectis (EPA:ALCLS) Using Debt In A Risky Way?

Jan 01
Is Cellectis (EPA:ALCLS) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Feb 07
A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Aug 09
Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Dec 14
Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher

Aug 07
Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher

CEO Compensation Analysis

How has Andre Choulika's remuneration changed compared to Cellectis's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$938kUS$938k

-US$37m

Sep 30 2024n/an/a

-US$84m

Jun 30 2024n/an/a

-US$79m

Mar 31 2024n/an/a

-US$78m

Dec 31 2023US$877kUS$875k

-US$109m

Sep 30 2023n/an/a

-US$92m

Jun 30 2023n/an/a

-US$97m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$744kUS$744k

-US$91m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$78m

Mar 31 2022n/an/a

-US$99m

Dec 31 2021US$879kUS$879k

-US$86m

Sep 30 2021n/an/a

-US$129m

Jun 30 2021n/an/a

-US$121m

Mar 31 2021n/an/a

-US$113m

Dec 31 2020US$1mUS$1m

-US$37m

Sep 30 2020n/an/a

-US$79m

Jun 30 2020n/an/a

-US$66m

Mar 31 2020n/an/a

-US$67m

Dec 31 2019US$1mUS$1m

-US$102m

Compensation vs Market: Andre's total compensation ($USD937.54K) is above average for companies of similar size in the French market ($USD306.73K).

Compensation vs Earnings: Andre's compensation has increased whilst the company is unprofitable.

CEO

Andre Choulika (59 yo)

26.3yrs

Tenure

US$937,539

Compensation

Dr. Andre Choulika, Ph.D. is the Founder of Cellectis S.A. and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. He is the Director of Cellectis...

Leadership Team

NamePositionTenureCompensationOwnership
Andre Choulika
Co-Founder26.3yrsUS$937.54k1.46%
€ 1.6m
David J. Sourdive
Co-Founderno dataUS$593.16k0.41%
€ 441.6k
Arthur Stril
CFO & Chief Business Officer1yrno data0.024%
€ 26.5k
Valerie Cros
Principal Financial Officer & Principal Accounting Officer3.4yrsno datano data
Jean Epinat
Chief Technological Officerno datano datano data
Philippe Duchateau
Chief Scientific Officer13.3yrsno data0.072%
€ 78.6k
Marie-Bleuenn Terrier
General Counsel & Secretary of the Board of Directors12.3yrsno data0.055%
€ 59.6k
Pascalyne Wilson
Director of Communicationsno datano datano data
Kyung Nam-Wortman
Executive VP & Chief Human Resources Officer4.5yrsno data0.029%
€ 31.0k
Stephan Reynier
Chief Regulatory & Pharmaceutical Compliance Officerno datano data0.045%
€ 48.5k
Steven Doares
Senior VP of US Manufacturing & Site Head of the Raleigh4.8yrsno data0.034%
€ 36.6k
Laurent Poirot
Senior Vice President of Immunologyno datano datano data

4.8yrs

Average Tenure

56yo

Average Age

Experienced Management: ALCLS's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andre Choulika
Co-Founder26.3yrsUS$937.54k1.46%
€ 1.6m
David J. Sourdive
Co-Founder25.3yrsUS$593.16k0.41%
€ 441.6k
Jean-Pierre Garnier
Independent Non-Executive Chairman4.5yrsUS$106.63k0%
€ 0
Laurent Arthaud
Director13.6yrsno datano data
Pierre Bastid
Independent Director13.6yrsUS$97.39k0.078%
€ 84.1k
Rainer Boehm
Independent Director7.9yrsUS$102.80k0%
€ 0
Dietger Niederwieser
Member of Clinical Advisory Board8.2yrsno datano data
Kanti Rai
Member of Clinical Advisory Board8.3yrsno datano data
Catherine Bollard
Member of Clinical Advisory Board8.2yrsno datano data
Ola Landgren
Member of Clinical Advisory Board8.2yrsno datano data
Marcela Maus
Member of Clinical Advisory Board8.2yrsno datano data
Stephan Grupp
Member of Clinical Advisory Board6.7yrsno datano data

8.2yrs

Average Tenure

60yo

Average Age

Experienced Board: ALCLS's board of directors are considered experienced (8.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 00:45
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cellectis S.A. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Jack AllenBaird
Huidong WangBarclays